产品描述: | Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression in patients with mild Alzheimer’s disease (AD). Azeliragon also can cross the blood-brain barrier (BBB) |
靶点: |
Amyloid-β;BetaAmyloid;advancedglycationendproducts |
体内研究: |
Azeliragon (100 mcg/d; intraperitoneal injection; every day) treatment reduces syngeneic islet graft and islet allograft in NOD and B6 mice (Islets were isolated from young prediabetic NOD/LtJ mice and transplanted into NOD mice with spontaneous diabetes; islets were isolated from WT BALB/c mice and transplanted into B6 mice with diabetes) |
参考文献: |
1. Burstein AH, et al. Assessment of Azeliragon QTc Liability Through Integrated, Model-Based Concentration QTc Analysis. Clin Pharmacol Drug Dev. 2019 May;8(4):426-435. 2. Bongarzone S, et al. Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective. J Med Chem. 2017 Sep 14;60(17):7213-7232. 3. Chen Y, et al. RAGE ligation affects T cell activation and controls T cell differentiation. J Immunol. 2008 Sep 15;181(6):4272-8. |
溶解性: |
Soluble in DMSO |
保存条件: |
RT |
配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
1 mM |
1.879 ml |
9.396 ml |
18.793 ml |
5 mM |
0.376 ml |
1.879 ml |
3.759 ml |
10 mM |
0.188 ml |
0.94 ml |
1.879 ml |
50 mM |
0.038 ml |
0.188 ml |
0.376 ml |
|
注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |